drugset / Trial / NCT00732186
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety of ipilimumab and dasatinib combination therapy in patients with CML
Timeline
- Start
- 2009-08
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Ipilimumab | Monoclonal antibody | 10 mg/kg | — |